journal
https://read.qxmd.com/read/36657435/antibiotic-resistance-in-dermatology-part-1-mechanisms-of-resistance
#1
JOURNAL ARTICLE
Austinn C. Miller, Susuana Adjei, Laurie A. Temiz, Stephen K. Tyring
Virtually any antibiotic can be used in dermatology given the broad range of conditions treated. With the widespread use of antibiotics and the rapid emergence of resistant organisms, it is important to understand the mechanisms at play that contribute to resistance.
January 2023: Skin Therapy Letter
https://read.qxmd.com/read/36657434/tralokinumab-for-moderate-to-severe-atopic-dermatitis-in-adults
#2
JOURNAL ARTICLE
Abrahim Abduelmula, Brian D Rankin, Asfandyar Mufti, Jensen Yeung, Vimal H Prajapati
Atopic dermatitis (AD) is a common, chronic, recurrent, immune-mediated inflammatory skin disease. Targeted treatment options remain limited. Tralokinumab (Adtralza®) is a promising, new systemic therapy that inhibits interleukin-13. It was recently approved by Health Canada and the US FDA for the treatment of moderate-to-severe AD in adults and may be used alone or with topical corticosteroids. Herein, we review the efficacy and safety of tralokinumab in adults, as demonstrated in clinical trials.
January 2023: Skin Therapy Letter
https://read.qxmd.com/read/36469561/acne-scars-an-update-on-management
#3
JOURNAL ARTICLE
Abdulhadi Jfri, Ali Alajmi, Mohammad Alazemi, Malika A Ladha
Acne vulgaris is a troubling skin disease known to have both physiologic and psychological effects on patients. Acne scars, a frequent complication, can further impact patients' quality of life. Scars result from an impairment in the healing process. Acne scars can be categorized as follows: atrophic scars (including ice pick, rolling, boxcar subtypes) and trophic (including hypertrophic and keloid scars), the latter being less common. Though various treatment approaches have been suggested, there is a lack of high-quality evidence on effective, type-specific acne scar approaches...
November 2022: Skin Therapy Letter
https://read.qxmd.com/read/36469536/selective-tyk2-inhibition-in-the-treatment-of-moderate-to-severe-chronic-plaque-psoriasis
#4
JOURNAL ARTICLE
Melinda J Gooderham, H Chih-Ho Hong, Ivan V Litvinov
Moderate to severe chronic plaque psoriasis may be difficult to control using current therapies, which has led to development of a novel class of therapy, selective tyrosine kinase 2 (TYK2) inhibitors, to address this unmet need. Oral deucravacitinib is a first-inclass selective TYK2 inhibitor, which has shown efficacy in moderate to severe chronic plaque psoriasis from two phase III pivotal trials (POETYK PSO-1 and PSO-2), whereby response rates were significantly higher with deucravacitinib vs. placebo or apremilast for Psoriasis Area Severity Index (PASI) 75 and static Physician's Global Assessment (sPGA) 0/1...
November 2022: Skin Therapy Letter
https://read.qxmd.com/read/36469487/toxic-epidermal-necrolysis-a-review-of-past-and-present-therapeutic-approaches
#5
REVIEW
Neha Singh, Mariana Phillips
Toxic epidermal necrolysis (TEN) is an immune mediated, severe cutaneous adverse drug reaction characterized by epidermal detachment affecting greater than 30% body surface area. The mortality rate of TEN exceeds 20% and is usually caused by infection and respiratory compromise. Withdrawal of the causative drug, supportive care, and adjuvant therapy improve prognosis. Over the past decade, randomized controlled trials and meta-analyses have supported a role for cyclosporine, tumor necrosis factor alpha inhibitors, and combination therapy with intravenous immune globulin and corticosteroids...
September 2022: Skin Therapy Letter
https://read.qxmd.com/read/36469458/extracorporeal-photopheresis-and-its-use-in-clinical-dermatology-in-canada
#6
REVIEW
François Lagacé, Elena Netchiporouk, Irina Turchin, Wayne Gulliver, Jan Dutz, Mark G Kirchhof, Popradi Popradi, Robert Gniadecki, Charles Lynde, Ivan V Litvinov
Extracorporeal photopheresis (ECP) is an immunomodulatory therapy that has been used for over 35 years to treat numerous conditions. ECP was initially approved by the US FDA in 1988 for the treatment of Sézary syndrome, a leukemic form of cutaneous T-cell lymphoma (CTCL). Although CTCL remains the only FDA-approved indication, ECP has since been used off-label for numerous other conditions, including graft-versus-host disease (GvHD), systemic sclerosis, autoimmune bullous dermatoses, Crohn's disease, and prevention of solid organ transplant rejection...
September 2022: Skin Therapy Letter
https://read.qxmd.com/read/35857917/tirbanibulin-for-the-treatment-of-actinic-keratosis-a-review
#7
REVIEW
Austinn C Miller, Susuana Adjei, Laurie A Temiz, Stephen K Tyring
Actinic keratosis (AK) is a common precancerous condition found on chronically sun-damaged skin, particularly on the face, scalp, arms, and legs. Early and effective treatment of AKs is important to prevent progression to squamous cell carcinoma. Many topical treatments for AKs are often limited because of poor tolerability, prolonged treatment duration, and reduced adherence. Tirbanibulin 1% ointment, a new topical field therapy for AKs, reduces these issues. It requires a consecutive 5-day application period and is effective, demonstrating complete (100%) clearance of AK lesions in 49% of patients, partial (>75%) clearance in 72%, and a median reduction in lesion count of 87...
July 2022: Skin Therapy Letter
https://read.qxmd.com/read/35857858/tazarotene-lotion-0-045-for-the-treatment-of-acne
#8
JOURNAL ARTICLE
Catherine Zip
Topical retinoids are recommended as first line therapy for the treatment of acne. Despite this recommendation, topical retinoids are underutilized, in part because of their tendency to cause cutaneous irritation. Tazarotene 0.045% lotion was developed using polymeric emulsion technology to provide an effective, well tolerated topical retinoid for the treatment of acne.
July 2022: Skin Therapy Letter
https://read.qxmd.com/read/35533371/sarecycline-a-narrow-spectrum-antibiotic
#9
JOURNAL ARTICLE
Susuana Adjei, Austinn C Miller, Laurie A Temiz, Stephen K Tyring
Tetracycline-class drugs have been used for first-line treatment of moderate-to-severe acne and rosacea for decades. Recently, a new third generation tetracycline, sarecycline, was US FDA-approved for the treatment of moderate-to-severe acne. This narrow-spectrum tetracycline-derived antibiotic has been shown to be effective with an improved safety profile.
May 2022: Skin Therapy Letter
https://read.qxmd.com/read/35533304/halobetasol-propionate-0-01-lotion-for-plaque-psoriasis-and-corticosteroid-responsive-dermatoses
#10
JOURNAL ARTICLE
Abrahim Abduelmula, Brian D Rankin, Ronald Vender, Jensen Yeung, Alim R Devani, Vimal H Prajapati
A novel topical corticosteroid, halobetasol propionate (HP) 0.01% lotion (Bryhali™), has recently been introduced for the treatment of plaque psoriasis and corticosteroid-responsive dermatoses in adults. Once daily application of HP 0.01% lotion is indicated for use up to 8 weeks. Treatment success for plaque psoriasis in the pivotal phase 3 clinical trials (defined as an Investigator Global Assessment [IGA] of clear/almost clear [IGA 0/1] with ≥2-grade improvement from baseline) occurred in over one-third of patients by week 8...
May 2022: Skin Therapy Letter
https://read.qxmd.com/read/35385631/transition-of-topical-therapy-formulation-in-psoriasis-insights-from-a-canadian-practice-reflective
#11
JOURNAL ARTICLE
David N Adam, Sonya J Abdulla, Patrick Fleming, Melinda J Gooderham, John Ashkenas, Clinton B McCracken
Patient preferences for psoriasis treatment may affect treatment adherence and disease control; changing topical formulation may improve adherence and patient acceptance of treatment. This study explored dermatologists' reasons for transitioning psoriasis patients from an ointment or gel (Dovobet®) formulation to an aerosol foam (Enstilar®) formulation of calcipotriol and betamethasone dipropionate (Cal/BD), and to assess the success of this transition. Medical records of 81 Canadian patients from 9 dermatologists were retrospectively reviewed for symptoms affecting quality of life, reasons for transitioning treatment, and whether transition was successful...
March 2022: Skin Therapy Letter
https://read.qxmd.com/read/35385630/plerixafor-on-a-whim-promise-or-fantasy-of-a-new-cxcr4-inhibitor-for-this-rare-but-important-syndrome
#12
REVIEW
Nickoo Merati, Sriraam Sivachandran, Abdulhadi Jfri, Moshe Ben-Shoshan, Donald C Vinh, Gizelle Popradi, Ivan V Litvinov
Warts, Hypogammaglobulinemia, Infections and Myelokathexis (WHIM) is a primary immunodeficiency syndrome. Patients with WHIM syndrome are more susceptible to human papillomavirus (HPV) infections and commonly present to a dermatologist with recalcitrant to treatment warts. Other cardinal features of WHIM syndrome include recurrent sinopulmonary bacterial infections, neutropenia/lymphopenia, low levels of immunoglobulins (IgG, IgA, IgM) and myelokathexis. Research demonstrated that truncating gain-of-function mutations of the C-X-C chemokine receptor type 4 gene (CXCR4) are responsible for this disease...
March 2022: Skin Therapy Letter
https://read.qxmd.com/read/35081305/janus-kinase-and-tyrosine-kinase-inhibitors-in-dermatology-a-review-of-their-utilization-safety-profile-and-future-applications
#13
REVIEW
Mojahed M K Shalabi, Benjamin Garcia, Kendall Coleman, Alfredo Siller, Austinn C Miller, Stephen K Tyring
Janus kinase inhibitors, also commonly referred to as JAK inhibitors, are a novel drug class that target and block cytokine signaling mediated by the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway, thereby regulating immune response and cell growth. Although JAK inhibitors are mainly used for rheumatological conditions such as rheumatoid arthritis, their application in the field of dermatology is actively being investigated. Tofacitinib is US FDA-approved for psoriatic arthritis and showing promise for treating psoriasis...
January 2022: Skin Therapy Letter
https://read.qxmd.com/read/35081302/topical-clascoterone-for-acne-vulgaris
#14
JOURNAL ARTICLE
Nicole E Burma, Taylor E Woo, Laurie Parsons
The pathogenesis of acne is multifactorial and involves inflammation, bacterial dysbiosis, and androgen stimulation. Existing systemic therapies target hormonal pathways to mitigate acne lesions; however, their use is limited to the female population and associated with systemic adverse effects. Clascoterone is the first topical therapy to target the hormonal pathogenesis of acne approved to treat acne vulgaris. In two identical phase 3 trials, clascoterone showed favorable efficacy over placebo in treating acne, with higher treatment success and a greater reduction in acne lesions...
January 2022: Skin Therapy Letter
https://read.qxmd.com/read/34871479/psoriasis-education-tool-for-patient-physician-decision-making-about-biologics-a-pilot-study
#15
JOURNAL ARTICLE
Marissa Nahirney, Matthew Hum, Pamela Mathura, Marlene Dytoc
Although biologics are well-studied, expertise regarding their use is often lacking. Many biologics have been added to the market in recent years with distinctive characteristics. This study was designed to create a tool to assist physicians involved in the care of patients with psoriasis undergoing biologic treatment. We used a quality improvement approach to develop and trial an educational visual aid to deliver comprehensive information about biologics in a convenient manner. As a pilot study, trialing this tool was carried out on a small scale to test the feasibility of both the study design and the visual aid itself, with 8 physician and 8 patients completing questionnaires evaluating the visual aid...
November 2021: Skin Therapy Letter
https://read.qxmd.com/read/34871475/fixed-combination-halobetasol-propionate-and-tazarotene-lotion-for-plaque-psoriasis
#16
JOURNAL ARTICLE
Lyn Guenther, Andrei Metelitsa, Vimal H Prajapati
A novel fixed combination lotion containing the super-potent corticosteroid halobetasol propionate 0.01% and retinoid tazarotene 0.045% (Duobrii™) has recently been introduced and indicated for the treatment of moderate to severe plaque psoriasis in adults. Studies have shown that there is synergy between the ingredients and that the product can be safely used intermittently for up to 1 year. Treatment success (i.e., Investigator Global Assessment [IGA] of clear/almost clear [IGA 0/1] and at least a 2-grade improvement from baseline) occurred in 58...
November 2021: Skin Therapy Letter
https://read.qxmd.com/read/34524781/hair-removal-practices-a-literature-review
#17
REVIEW
Cindy Na-Young Kang, Monica Shah, Charles Lynde, Patrick Fleming
Hair removal practices have evolved from adhering to social, cultural, and religious traditions to meeting aesthetic standards. Hair removal methods can be divided into two categories: 1) depilation, which involves removing the hair shaft and includes shaving and chemical depilatories, and 2) epilation, which involves removing the hair shaft, follicle, and bulb, and includes plucking, threading, waxing, sugaring, lasers, intense pulsed light system, electrolysis, and photodynamic therapy. Furthermore, an eflornithine hydrochloride 13...
September 2021: Skin Therapy Letter
https://read.qxmd.com/read/34524780/labeling-laws-for-personal-care-products-potential-pitfalls-for-the-consumer
#18
JOURNAL ARTICLE
Evelyne Tantry, Ariadna Perez-Sanchez, Shelly Fu, Shravya Potula, Rajani Katta
Consumers of personal care products must be made aware of the potential pitfalls that arise from current labeling practices and regulations. For example, terms such as "hypoallergenic", "sensitive skin", and "baby product" lack legal definitions, and terms such as "fragrance-free" are frequently misinterpreted. Personal care products are a general category that includes such items as cosmetics, drugs, dietary supplements, and consumer goods. This overview of current US FDA regulations of products in this category reviews pertinent regulatory policies and highlights potential consumer pitfalls when evaluating product labels...
September 2021: Skin Therapy Letter
https://read.qxmd.com/read/34347397/moisturizers-and-cleansers-in-the-management-of-skin-conditions-caused-by-personal-protective-equipment-and-frequent-handwashing
#19
REVIEW
Sara Mirali, Patrick Fleming, Charles W Lynde
During the COVID-19 pandemic, prolonged usage of personal protective equipment (PPE) and frequent handwashing has exacerbated or caused skin diseases, particularly amongst frontline workers. Skin conditions, such as atopic dermatitis, irritant contact dermatitis, and hand eczema, affect patients’ quality of life and their ability to work. These conditions can be managed by frequent moisturization and washing with gentle cleansers. In this review, we discuss the properties of effective moisturizers and cleansers for patients with skin diseases related to enhanced infection control procedures...
July 2021: Skin Therapy Letter
https://read.qxmd.com/read/34347259/rosacea-an-update-in-diagnosis-classification-and-management
#20
JOURNAL ARTICLE
Cindy Na-Young Kang, Monica Shah, Jerry Tan
The diagnosis and classification of rosacea has been modified to reflect presenting features. On exclusion of differentials, the diagnosis of rosacea is based on the presence of either (1) phymatous changes, or (2) centrofacial persistent erythema. In their absence, diagnosis can be established by presence of any two of: flushing/transient erythema, papules and pustules, telangiectases, or ocular manifestations. Management of rosacea depends on presenting feature(s), their severity, and impact. General management includes gentle skin care, sun protection, and trigger avoidance...
July 2021: Skin Therapy Letter
journal
journal
34395
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.